Can Contrast-Enhanced Spectral Mammography (CESM) Reduce Benign Breast Biopsy?

Table 1

Histopathologic diagnosis of the 83 enhancing lesions.

Histopathology of enhancing malignant lesions (true positive)	BI-RADS 4A	BI-RADS 4B	BI-RADS 4C	BI-RADS 5	Frequency (%)
Invasive ductal carcinoma (IDC)	0	1	23	19	43 (79.6)
Invasive lobular carcinoma (ILC)	0	2	2	0	4 (7.4)
Ductal carcinoma in situ (DCIS)	0	1	1	1	3 (5.6)
Mucinous carcinoma	0	0	2	0	2 (3.7)
Mixed invasive ductal carcinoma and invasive lobular carcinoma	0	0	1	0	1 (1.9)
Invasive papillary carcinoma	0	1	0	0	1 (1.6)
Total	0	5	29	20	54 (100.0)
Histopathology of enhancing benign lesions (false positive)	BI-RADS 4A	BI-RADS 4B	BI-RADS 4C	BI-RADS 5	Frequency (%)
Fibroadenoma	4	8	1	0	13 (44.8)
Intraductal papilloma	2	4	0	0	6 (20.7)
Nodular adenosis	1	3	0	0	4 (13.8)
Benign breast tissue	0	2	0	0	2 (6.9)
Fat necrosis	0	1	0	0	1 (3.4)
Flat epithelial atypia	0	1	0	0	1 (3.4)
Benign phyllodes tumour	0	1	0	0	1 (3.4)
Ruptured cyst	1	0	0	0	1 (3.4)
Total	8	20	1	0	29 (100.0)